Literature DB >> 27354963

Failure of memantine to "reverse" quinpirole-induced hypomotility.

Francesca Demontis1, Gino Serra1.   

Abstract

AIM: To evaluate antidepressant-like effect of memantine in a rat model.
METHODS: Male Wistar rats were treated intraperitoneally with either vehicle, memantine (10 mg/kg) or imipramine (20 mg/kg), for 3 wk. Twenty-four hour after the last treatment animals were challenged with quinpirole (0.3 mg/kg s.c.) and tested for motor activity. After 1 h habituation to the motility cages, the motor response was recorded for the following 45-min and the data were collected in 5-min time bins.
RESULTS: As expected, chronic treatment with imipramine potentiated the locomotor stimulant effect of quinpirole. On the contrary, chronic memantine administration failed to induce the behavioral supersensitivity to the dopamine agonist.
CONCLUSION: The results show that memantine, at variance with antidepressant treatments, fails to induce dopaminergic behavioral supersensitivity. This observation is consistent with the results of preclinical and clinical studies suggesting that memantine does not have an acute antidepressant action but does have an antimanic and mood-stabilizing effect.

Entities:  

Keywords:  Bipolar disorder; D2 sensitization; Depression; Imipramine; Memantine; Mood stabilizer

Year:  2016        PMID: 27354963      PMCID: PMC4919260          DOI: 10.5498/wjp.v6.i2.215

Source DB:  PubMed          Journal:  World J Psychiatry        ISSN: 2220-3206


  43 in total

1.  Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus.

Authors:  A Bouron; J Y Chatton
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590

Review 2.  Role of the mesolimbic dopamine system in the mechanism of action of antidepressants.

Authors:  G Serra; M Collu; P S D'Aquila; G L Gessa
Journal:  Pharmacol Toxicol       Date:  1992

3.  The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats.

Authors:  G Skuza; Z Rogóz
Journal:  J Physiol Pharmacol       Date:  2006-06       Impact factor: 3.011

4.  Behavioural sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine-treated rats.

Authors:  M Collu; A S Poggiu; P Devoto; G Serra
Journal:  Eur J Pharmacol       Date:  1997-03-19       Impact factor: 4.432

5.  Memantine in the management of affective recurrences of bipolar disorders after the discontinuation of long-term lithium treatment: three case histories.

Authors:  Giulia Serra; Lavinia De Chiara; Giovanni Manfredi; Alexia E Koukopoulos; Gabriele Sani; Paolo Girardi; Athanasios Koukopoulos; Gino Serra
Journal:  Ther Adv Psychopharmacol       Date:  2014-02

6.  Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.

Authors:  Eric J Lenze; Elizabeth R Skidmore; Amy E Begley; John W Newcomer; Meryl A Butters; Ellen M Whyte
Journal:  Int J Geriatr Psychiatry       Date:  2011-12-16       Impact factor: 3.485

7.  Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder.

Authors:  Giulia Serra; Athanasios Koukopoulos; Lavinia De Chiara; Alexia E Koukopoulos; Leonardo Tondo; Paolo Girardi; Ross J Baldessarini; Gino Serra
Journal:  J Clin Psychiatry       Date:  2015-01       Impact factor: 4.384

8.  Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial.

Authors:  Amit Anand; Abigail D Gunn; Gavriel Barkay; Harish S Karne; John I Nurnberger; Sanjay J Mathew; Samiran Ghosh
Journal:  Bipolar Disord       Date:  2012-02       Impact factor: 6.744

9.  Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.

Authors:  Eric G Smith; Kristina M Deligiannidis; Christine M Ulbricht; Chelsea S Landolin; Jayendra K Patel; Anthony J Rothschild
Journal:  J Clin Psychiatry       Date:  2013-10       Impact factor: 4.384

10.  An open-label, flexible-dose study of memantine in major depressive disorder.

Authors:  James M Ferguson; Richard N Shingleton
Journal:  Clin Neuropharmacol       Date:  2007 May-Jun       Impact factor: 1.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.